Times Square Investment Journal
  • Home
  • News
  • Company Insights
  • Stocks
  • Previews
  • Personal Finance
Select Page
3D Virtual Tours Let Homebuyers Bid Without Visiting — But Are They Worth the Risk?

3D Virtual Tours Let Homebuyers Bid Without Visiting — But Are They Worth the Risk?

by Juan Lasso | Dec 18, 2025

As 3D virtual tours turn house and apartment hunting into a more immersive, click-through experience, buyers are growing more comfortable evaluating, and even bidding on homes entirely online.  According to a Realtor.com 2025 study, half of buyers say they would...
As AI Cools, Brad Jacobs’ QXO Heats Up With a Back-to-Basics Roll-Up Strategy

As AI Cools, Brad Jacobs’ QXO Heats Up With a Back-to-Basics Roll-Up Strategy

by Juan Lasso | Dec 4, 2025

As Wall Street wrestles with the limits of the AI boom, some entrepreneurs are doubling down on industries that may lack flash but can shine under the right growth strategy. Enter Brad Jacobs, a veteran dealmaker who has built a reputation for turning overlooked,...
Thermo Fisher Edges Back Toward Normalcy Amid Tariff, Budget Challenges

Thermo Fisher Edges Back Toward Normalcy Amid Tariff, Budget Challenges

by Juan Lasso | Nov 13, 2025

Thermo Fisher Scientific has held its ground even amid a wild run of economic policy shifts. The company posted solid revenue growth in its core product line and raised its full-year outlook for the second time this year despite tariffs and research funding cuts. The...
Federal Research Cuts Could Reverberate Through Thermo Fisher Scientific

Federal Research Cuts Could Reverberate Through Thermo Fisher Scientific

by Juan Lasso | Nov 10, 2025

In labs stretching from Illinois to North Carolina and beyond, Thermo Fisher Scientific’s instruments are impossible to miss.  At Duke University, environmental chemist Heather Stapleton says a Thermo Fisher mass spectrometer sits “at the heart” of her team’s...
Trump’s Unpredictable Pharma Policies Could Pinch Thermo Fisher’s Bottom Line

Trump’s Unpredictable Pharma Policies Could Pinch Thermo Fisher’s Bottom Line

by Juan Lasso | Oct 1, 2025

President Trump’s tariff hike and drug pricing agenda have injected fresh uncertainty into the pharmaceutical sector. Thermo Fisher Scientific could end up caught in the crossfire. Analysts warn that drugmakers, dependent on long-term contracts and stable pricing, may...
« Older Entries

Latest Posts

  • Trump’s policies dampened tourism. The slowdown now hurts American businesses.
  • America’s wealth is growing. The number of financial advisors is not.
  • Albemarle Corporation Finally Adapted to the Lithium Bust. Now A Boom is Around the Corner.
  • Stock Market Disagrees with Trump on Renewables
  • Builder Mortgage Deals Put Southern Buyers At Risk

About

Welcome to Investment Journal, a site covering the world of business right from Times Square. The site is produced by reporters at a newsroom in Times Square at the New York City News Service and the Craig Newmark Graduate School of Journalism at CUNY. Email your comments to greg.david@journalism.cuny.edu.

  • Facebook
  • Twitter
  • Google
  • RSS